Normunity

Executive Summary

Normunity is a private biotechnology company pioneering novel anti-cancer therapies that target the immune-tumor interface. Founded in 2021 and based in New Haven, Connecticut, the company leverages proprietary platforms developed with the Lieping Chen lab at Yale to identify 'Immuno-smart' targets—tumor-specific cell-surface proteins co-opted by tumors to drive local immune suppression. Its pipeline includes therapeutic antibodies, bispecifics, and payload-carrying biologics, with lead T cell engager program NRM-823 now in clinical trials. Normunity's approach aims to reprogram the tumor microenvironment and unlock potent anti-tumor immunity, addressing key limitations of current immunotherapies. The company's focus on novel, tumor-exclusive targets positions it to potentially overcome resistance and improve patient outcomes across multiple cancer types.

Upcoming Catalysts (preview)

• Q4 2026Initial clinical data from NRM-823 Phase 1/2 trial45% success
• Q1 2027Nomination of second clinical candidate from Immuno-smart platform60% success
• Q2 2027Strategic partnership or collaboration for pipeline expansion40% success